The STAT+ article summarizes the Massachusetts Biotechnology Council’s annual “industry snapshot” and reports a contraction in the state’s biopharma workforce in 2025. According to the snapshot as presented in the source, the total number of people employed in Massachusetts’ biopharma sector declined to 113,503 in 2025. That decline represents a loss of roughly 3,600 jobs compared with 2024 and a 3.1% reduction year over year.
The article notes that this is the first year-over-year employment decline in the sector in Massachusetts since at least 2002, making the 2025 drop a notable departure from more than two decades of growth or stability.
The central numeric findings reported are: a workforce of 113,503 in 2025, down approximately 3,600 positions from the prior year, equating to a 3.1% decline. The source frames these numbers as part of the Massachusetts Biotechnology Council’s regular industry snapshot, which tracks employment and other industry indicators.
The article presents those numbers without additional breakdowns by job type, region within the state, company size, or subsector; such granular details were not reported in the source.
The snapshot and the STAT+ coverage attribute the decline to general industry headwinds and specific concerns about federal research funding. The source explicitly links the workforce reduction to uncertainty about federal funding for scientific research and broader pressures facing the biopharma industry.
No further quantified attribution (for example, how much of the job loss is tied to funding uncertainty versus other factors) was provided in the source article.
The STAT+ article highlights a visible consequence of the sector’s earlier expansion: many lab buildings in Greater Boston that were developed or occupied when venture capital flowed during the early pandemic period are now empty. The reporting characterizes those vacant lab spaces as a symbol of overexpansion, invoking the phrase “irrational exuberance,” used by former Federal Reserve chairman Alan Greenspan, to describe the mismatch between prior expectations and current demand.
The story connects empty lab real estate to the employment decline, portraying vacant facilities as both a marker of and a contributor to the changed industry environment. Specific counts of empty buildings, vacancy rates, or real-estate metrics were not reported in the source.
The STAT+ summary cites the Massachusetts Biotechnology Council’s annual snapshot as its source for employment figures and context. However, the article as reproduced in the source does not provide the snapshot’s methodological details, nor does it include deeper breakdowns such as:
Those methodological elements and more granular data points were not reported in the source piece.
The article in STAT+ reproduces reporting attributed to Jonathan Saltzman of the Boston Globe and was published Aug. 25, 2026. It presents findings from the Massachusetts Biotechnology Council trade group’s annual industry snapshot and frames the 2025 decline in employment as the first such drop since at least 2002. The source labels the item as exclusive to STAT+ subscribers; the full STAT+ article requires subscription access to read beyond the excerpt provided in the source.
This rewritten summary limits itself to the facts and descriptions contained in the original STAT+ article and the Massachusetts Biotechnology Council snapshot as cited there. Any methodological specifics, additional numeric breakdowns, or subsequent developments were not reported in the source and are therefore not included here.